Business Description
Tenon Medical, Inc., a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain. It also provides Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI Joint along its longitudinal axis. Tenon Medical, Inc. was incorporated in 2012 and is headquartered in Los Gatos, California.
Business History
Price Overview
Last updated: Jun 27, 2026 9:03am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -1.70
Total Equity: $5.04M
Shares: 7,384,000
Total Debt: $0.00
Cash: $3.76M
EBITDA: -$12.03M
Total Debt: $0.00
Cash: $3.76M
Revenue: $3.94M
Shares: 7,384,000
Revenue: $3.94M
Revenue: $3.94M
Revenue: $3.94M
Total Equity: $5.04M
Tax Rate: 0.0%
Equity: $5.04M
Total Debt: $0.00
Cash: $3.76M
Current Liabilities: $3.21M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $5.04M
Shares: 7,384,000
Shares: 7,384,000
CapEx: -$273,000
Shares: 7,384,000
Stock Price: $0.51
Net Income: -$12.56M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 27, 2026 7:55am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $160,000 | $691,000 | $2.9M | $3.3M | $3.9M |
| Cost of Revenue | $55,000 | $1.3M | $1.7M | $1.6M | $1.6M |
| Gross Profit | $105,000 | $-641,000 | $1.2M | $1.7M | $2.4M |
| Operating Expenses | $6.6M | $18.1M | $17.0M | $15.5M | $15.2M |
| Operating Income | -$6.5M | -$18.7M | -$15.7M | -$13.8M | -$12.8M |
| Net Income | -$7.0M | -$18.9M | -$15.6M | -$13.7M | -$12.6M |
| EBITDA | -$6.3M | -$18.3M | -$15.1M | -$13.0M | -$12.0M |
| EPS | $-624.38 | $-187.30 | $-68.64 | $-11.26 | $-1.70 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 7:55am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.9M | $2.1M | $2.4M | $6.5M | $3.8M |
| Total Current Assets | $7.7M | $9.3M | $3.9M | $8.2M | $6.8M |
| Total Assets | $9.3M | $11.1M | $6.3M | $9.8M | $10.8M |
| Current Liabilities | $15.3M | $2.5M | $3.1M | $1.9M | $3.2M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $29.8M | $4.8M | $5.6M | $3.9M | $5.7M |
| Total Equity | -$20.6M | $6.3M | $778,000 | $6.0M | $5.0M |
| Retained Earnings | -$20.6M | -$39.5M | -$55.1M | -$68.7M | -$81.3M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 7:55am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.3M | -$12.0M | -$12.2M | -$9.9M | -$10.7M |
| Capital Expenditure | $-102,000 | $-847,000 | $-361,000 | $-186,000 | $-273,000 |
| Free Cash Flow | -$4.4M | -$12.9M | -$12.5M | -$10.1M | -$11.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $2.7M | $-788,000 | $299,000 | $4.1M | -$2.8M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 7:55am (1h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$9.7M $7.8M – $11.6M
|
$20.0M $17.2M – $22.8M
|
$28.7M $24.7M – $32.8M
|
$40.4M $34.7M – $46.1M
|
| EBITDA |
-$9.7M -$11.6M – -$7.8M
|
-$20.0M -$22.8M – -$17.2M
|
-$28.7M -$32.8M – -$24.7M
|
-$40.4M -$46.1M – -$34.7M
|
| Net Income |
-$4.5M -$5.2M – -$3.7M
|
-$2.2M -$2.6M – -$1.8M
|
$-738,400 $-874,191 – $-602,606
|
$738,400 $602,606 – $874,191
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 7:55am (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +331.9% | +323.7% | +11.9% | +20.4% |
| Gross Profit Growth | -710.5% | +293.6% | +37.9% | +37.8% |
| Operating Income Growth | -189.8% | +16.0% | +12.5% | +7.1% |
| Net Income Growth | -168.4% | +17.6% | +12.2% | +8.2% |
| EBITDA Growth | -188.0% | +17.2% | +14.2% | +7.4% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 7:55am (1h ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-05-01 | Geist Wyatt D. | A-Award | 136,401.00 | $0.00 | $0 |
| 2026-05-01 | Grawey Nathaniel A. | A-Award | 68,201.00 | $0.00 | $0 |
| 2026-03-03 | Williamson Kevin | M-Exempt | 1,041.00 | $0.00 | $0 |
| 2026-03-03 | Williamson Kevin | M-Exempt | 1,041.00 | $0.00 | $0 |
| 2026-01-01 | FOSTER STEVEN M | M-Exempt | 140,936.00 | $0.00 | $0 |
| 2026-01-01 | FOSTER STEVEN M | M-Exempt | 140,936.00 | $0.00 | $0 |
| 2026-01-01 | Hochschuler Stephen | M-Exempt | 10,732.00 | $0.00 | $0 |
| 2026-01-01 | Hochschuler Stephen | M-Exempt | 10,732.00 | $0.00 | $0 |
| 2026-01-05 | Hochschuler Stephen | F-InKind | 3,327.00 | $0.93 | $3,098 |
| 2026-01-01 | WEIGLE ROBERT K | M-Exempt | 10,732.00 | $0.00 | $0 |
| 2026-01-01 | WEIGLE ROBERT K | M-Exempt | 10,732.00 | $0.00 | $0 |
| 2026-01-05 | WEIGLE ROBERT K | F-InKind | 3,413.00 | $0.93 | $3,174 |
| 2026-01-01 | GINN RICHARD | M-Exempt | 126,577.00 | $0.00 | $0 |
| 2026-01-01 | GINN RICHARD | M-Exempt | 126,577.00 | $0.00 | $0 |
| 2026-01-05 | GINN RICHARD | F-InKind | 47,426.00 | $0.93 | $44,111 |
| 2026-01-01 | Ferrari Richard | M-Exempt | 64,478.00 | $0.00 | $0 |
| 2026-01-01 | Ferrari Richard | M-Exempt | 64,479.00 | $0.00 | $0 |
| 2026-01-01 | Jacques Kristine M | M-Exempt | 583.00 | $0.00 | $0 |
| 2026-01-01 | Jacques Kristine M | M-Exempt | 10,146.00 | $0.00 | $0 |
| 2026-01-01 | Jacques Kristine M | M-Exempt | 10,146.00 | $0.00 | $0 |
Narrative Economics
market-narrative step).